GoodRx Holdings Financial Statements (GDRX)

GoodRx Holdingssmart-lab.ru %   2020 2021 2022 2022 2023   LTM ?
Report date 12.03.2021 01.03.2022 31.12.2022 01.03.2023 29.02.2024   09.05.2024
Currency USD USD USD USD USD   USD
Financial report URL  
Revenue, bln rub ? 550.7 745.4 766.6 766.6 750.3   764.2
Operating Income, bln rub -275.7 13.4 1.74 11.0 51.4   -15.0
EBITDA, bln rub ? -257.1 48.0 65.2 65.2 163.1   109.0
Net profit, bln rub ? -293.6 -25.3 -32.8 -32.8 -8.87   -6.59
OCF, bln rub ? 131.3 178.8 146.8 146.8 138.3   148.6
CAPEX, bln rub ? 35.8 34.5 55.2 55.2 55.8   62.1
FCF, bln rub ? 95.5 144.3 91.6 91.6 82.5   86.5
Dividend payout, bln rub 0.000 0.000 0.000 0.000 0.000   0.000
Ordinary share dividend yield, % 0.00% 0.00% 0.00% 0.00% 0.00%   0.00%
Dividend payout ratio, % 0.00% 0.00% 0.00% 0.00% 0.00%   0
OPEX, bln rub 796.8 685.3 699.7 699.7 528.8   658.2
Cost of production, bln rub 29.6 46.7 65.1 65.1 170.1   121.0
R&D, bln rub 61.8 125.9 143.1 143.1 133.4   133.4
Interest expenses, bln rub 27.9 23.6 34.2 34.2 56.7   58.2
Assets, bln rub 1 470 1 608 1 605 1 605 1 589   1 454
Net Assets, bln rub ? 711.4 831.7 814.8 814.8 762.0   631.1
Debt, bln rub 704.9 702.3 65.2 717.0 711.1   710.2
Cash, bln rub 968.7 941.1 757.2 757.2 672.3   533.3
Net debt, bln rub -263.8 -238.8 -691.9 -40.1 38.8   176.9
Ordinary share price, rub 40.3 32.7 4.66 4.66 6.70   5.29
Number of ordinary shares, mln 391.7 400.6 412.9 412.9 410.3   390.0
Market cap, bln rub 15 800 13 090 1 924 1 924 2 749   2 063
EV, bln rub ? 15 536 12 852 1 232 1 884 2 788   2 240
Book value, bln rub 394 368 283 213 195   58
EPS, rub ? -0.75 -0.06 -0.08 -0.08 -0.02   -0.02
FCF/share, rub 0.24 0.36 0.22 0.22 0.20   0.22
BV/share, rub 1.00 0.92 0.69 0.52 0.47   0.15
EBITDA margin, % ? -46.7% 6.44% 8.50% 8.50% 21.7%   14.3%
Net margin, % ? -53.3% -3.39% -4.28% -4.28% -1.18%   -0.86%
FCF yield, % ? 0.60% 1.10% 4.76% 4.76% 3.00%   4.19%
ROE, % ? -41.3% -3.04% -4.03% -4.03% -1.16%   -1.04%
ROA, % ? -20.0% -1.57% -2.05% -2.05% -0.56%   -0.45%
P/E ? -53.8 -518.3 -58.6 -58.6 -310.0   -313.2
P/FCF 165.4 90.7 21.0 21.0 33.3   23.9
P/S ? 28.7 17.6 2.51 2.51 3.66   2.70
P/BV ? 40.1 35.6 6.80 9.04 14.1   35.5
EV/EBITDA ? -60.4 267.7 18.9 28.9 17.1   20.6
Debt/EBITDA 1.03 -4.97 -10.6 -0.62 0.24   1.62
R&D/CAPEX, % 172.6% 365.3% 259.2% 259.2% 239.3%   214.9%
CAPEX/Revenue, % 6.51% 4.62% 7.20% 7.20% 7.43%   8.13%
GoodRx Holdings shareholders